Gemigliptin Attenuates Renal Fibrosis Through Down-Regulation of the NLRP3 Inflammasome

Jung Beom Seo; Yeon-Kyung Choi; Hye-In Woo; Yun-A Jung; Sungwoo Lee; Seunghyeong Lee; Mihyang Park; In-Kyu Lee; Gwon-Soo Jung; Keun-Gyu Park

doi:10.4093/dmj.2018.0181

Diabetes Metab J > Volume 43(6); 2019 > Article

Seo, Choi, Woo, Jung, Lee, Lee, Park, Lee, Jung, and Park: Gemigliptin Attenuates Renal Fibrosis Through Down-Regulation of the NLRP3 Inflammasome

Original Article

Complications

Diabetes & Metabolism Journal 2019;43(6):830-839.

Published online: March 05, 2019

DOI: https://doi.org/10.4093/dmj.2018.0181

Gemigliptin Attenuates Renal Fibrosis Through Down-Regulation of the NLRP3 Inflammasome

Jung Beom Seo^1,^*

, Yeon-Kyung Choi^1,^*

, Hye-In Woo¹, Yun-A Jung¹, Sungwoo Lee², Seunghyeong Lee^3,⁴, Mihyang Park^3,⁴, In-Kyu Lee¹, Gwon-Soo Jung²

, Keun-Gyu Park¹

¹Division of Endocrinology and Metabolism, Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, Korea.

²New Drug Development Center, Daegu-Gyeongbuk Medical Innovation Foundation, Daegu, Korea.

³Department of Biomedical Science, Graduate School, Kyungpook National University, Daegu, Korea.

⁴BK21 Plus KNU Biomedical Convergence Program, Kyungpook National University, Daegu, Korea.

Corresponding author: Keun-Gyu Park. Division of Endocrinology and Metabolism, Department of Internal Medicine, School of Medicine, Kyungpook National University, 130 Dongdeok-ro, Jung-gu, Daegu 41944, Korea. kpark@knu.ac.kr

Corresponding author: Gwon-Soo Jung. New Drug Development Center, Daegu-Gyeongbuk Medical Innovation Foundation, 88 Dongnae-ro, Dong-gu, Daegu 41061, Korea. gsjung@dgmif.re.kr

*Jung Beom Seo and Yeon-Kyung Choi contributed equally to this study as first authors.

Received September 13, 2018 Accepted November 29, 2018

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background

The hypoglycemic drugs dipeptidyl peptidase-4 (DPP-4) inhibitors have proven protective effects on diabetic kidney disease, including renal fibrosis. Although NOD-like receptor protein 3 (NLRP3) inflammasome activation is known to play an important role in the progression of renal fibrosis, the impact of DPP-4 inhibition on NLRP3-mediated inflammation while ameliorating renal fibrosis has not been fully elucidated. Here, we report that the renoprotective effect of gemigliptin is associated with a reduction in NLRP3-mediated inflammation in a murine model of renal fibrosis.

Methods

We examined the effects of gemigliptin on renal tubulointerstitial fibrosis induced in mice by unilateral ureteral obstruction (UUO). Using immunohistochemical and Western blot analysis, we quantitated components of the NLRP3 inflammasome in kidneys with and without gemigliptin treatment, and in vitro in human kidney tubular epithelial human renal proximal tubule cells (HK-2) cells, we further analyzed the effect of gemigliptin on transforming growth factor-β (TGF-β)-stimulated production of profibrotic proteins.

Results

Immunohistological examination revealed that gemigliptin ameliorated UUO-induced tubular atrophy and renal fibrosis. Gemigliptin-treated kidneys showed a reduction in levels of NLRP3, apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC), caspase-1, and interleukin-1β, which had all been markedly increased by UUO. In line with the in vivo results, TGF-β markedly increased NLRP3 inflammasome markers, which were attenuated by gemigliptin treatment. Furthermore, gemigliptin treatment attenuated phosphorylated nuclear factor-κB levels, which had been increased in the UUO kidney as well as in TGF-β-treated cultured renal cells.

Conclusion

The present study shows that activation of the NLRP3 inflammasome contributes to UUO-induced renal fibrosis and the renoprotective effect of gemigliptin is associated with attenuation of NLRP3 inflammasome activation.

Keywords: Dipeptidyl-peptidase IV inhibitors; Fibrosis; Inflammasomes; Kidney; LC15-0444 (Gemigliptin)

INTRODUCTION

Diabetic kidney disease (DKD) is the most common microvascular complication of diabetes and accounts for the majority of cases of end-stage renal disease (ESRD) [1]. The most common predisposing factor of ESRD is tubulointerstitial injury, mediated by processes such as interstitial fibrosis and inflammation [2]. Accumulating evidence demonstrates that mononuclear inflammatory cells are involved in damaging the renal interstitium and that persistent inflammation contributes to tubulointerstitial fibrosis [3,4]. Thus, understanding the mechanisms regulating inflammation in ESRD is likely to aid development of an effective therapeutic strategy for preventing tubulointerstitial fibrosis.

Dipeptidyl peptidase-4 (DPP-4) inhibitors (also known as gliptins) have proven protective effects on DKD. Their glucose lowering effects are mediated through decreasing the degradation of glucagon-like peptide 1 (GLP-1) [5]. As DPP-4 is localized on the surface of many cell types, including endothelial cells, kidney epithelial cells, and T-cells, many studies have demonstrated that DPP-4 inhibitors have pleiotropic effects in various organ systems [6]. In terms of expression per weight of organ, the kidney bears the highest levels of DPP-4 and, as DPP-4 induces inflammation, the protective effect of gliptins on renal fibrosis have been extensively investigated [6]. Linagliptin was found to ameliorate kidney fibrosis in streptozotocin-induced diabetic mice [7], and the renoprotective effect of alogliptin was demonstrated in mice with unilateral ureteral obstruction (UUO)-induced renal interstitial fibrosis [8]. Previously, we also demonstrated that gemigliptin plays a role in the prevention of DKD, regardless of its glucose-lowering effect [9].

The inflammasomes are a group of cytosolic protein complexes that function as immune system receptors and sensors in response to microbial infection and cellular damage [10]. Among the NOD-like receptors (NLRs), which sense whole pathogens or toxins and regulate the immune response, NOD2 and NOD-like receptor protein 3 (NLRP3) are the best understood [11]. The NLRP3 inflammasome and its initiation of production of proinflammatory cytokines have been investigated in many inflammatory settings including atherosclerosis, rheumatic diseases, microbial infection, and chronic inflammatory diseases [12,13,14]. Upon activation, the NLRP3 proteins oligomerize and recruit the adaptor protein apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC), and caspase-1, which assemble to form the inflammasome, and which leads to the conversion of the cytokine precursors pro-interleukin 1β (pro-IL-1β) and pro-IL-18 into biologically active IL-1β and IL-18, respectively [15]. Recently, growing evidence has revealed that the inflammasome significantly contributes to the progression of chronic kidney disease (CKD), including both tubulointerstitial and glomerular disease [12]. The NLRP3 inflammasome is activated in the UUO-induced tubular interstitial inflammation model of renal fibrosis (UUO kidney), whereas Nlrp3-deficient mice have less tubular injury and inflammation compared with the wild type [3]. However, the effect of gemigliptin on NLRP3 inflammasome activation in a model of renal fibrosis has not been fully investigated.

Here, we investigated whether the anti-fibrotic effect of gemigliptin in the UUO kidney is related to changes in NLRP3 inflammasome activity. In addition, we evaluated the effect of gemigliptin on the transforming growth factor-β (TGF-β)/nuclear factor-κB (NF-κB) signaling pathway, known to be a primary pathogenic factor in renal fibrosis and a potential mechanism underlying the effect of gemigliptin, in vivo and in vitro.

METHODS

Experimental design

For UUO-induced renal fibrosis, after a midabdominal incision under anesthesia using pentobarbital (50 mg/kg), the left ureter of C57BL6 mice was ligated with 5-0 silk suture at two separate points and cut between the two ligation points. After UUO, mice were orally administered 300 mg/kg/day gemigliptin. The dose of gemigliptin used in this study was determined by preciously published studies [9,16,17]. Fourteen days after UUO and gemigliptin treatment, mice were euthanized, and their left kidneys were removed, cut in thirds, fixed in 4% paraformaldehyde, and either embedded in paraffin for histologic examination or frozen in liquid nitrogen for the isolation of protein.

Histologic and morphologic analysis

Kidneys were fixed by immersion in phosphate-buffered saline containing 4% paraformaldehyde overnight and then embedded in paraffin. Sections (4 µm) were cut and deparaffinized in xylene, followed by rehydration in a graded series of ethanol. Staining was performed using hematoxylin and eosin (H&E), and Sirius red. Immunohistochemical (IHC) staining was performed using primary antibodies against the fibronectin (BD Biosciences, San Jose, CA, USA), plasminogen activator inhibitor 1 (PAI-1; BD Biosciences), and type I collagen (Abcam, Cambridge, UK), and NLRP3 (Novus Biologicals, Littleton, CO, USA), ASC, caspase-1, IL-1β (Santa Cruz Biotechnology, Santa Cruz, CA, USA), CD-26 (Abcam), and NF-κB (Cell Signaling Technology, Danvers, MA, USA), followed by horseradish peroxidase-conjugated anti-mouse or anti-rabbit immunoglobulin G secondary antibodies (Dako, Glostrup, Denmark), according to the manufacturer's instructions. Renal fibrotic areas were quantitated by morphometric analysis using an MRc5 Carl Zeiss light microscope (Oberkochen, Germany) equipped with an imaging system and iSolution DT version 7.7 software (IMT i-Solution, Coquitlam, BC, Canada). Sirius red-positive areas and immunostaining for fibronectin, type I collagen, PAI-1, NRLP3, ASC, Caspase-1, and IL-1β in the renal fibrotic regions (brown color) were quantitated by computer-based morphometric analysis. All data were normalized to the control and expressed as fold increase relative to the control.

Cell culture

Human kidney proximal tubular epithelial human renal proximal tubule cells (HK-2) cells were purchased from the American Type Culture Collection (Manassas, VA, USA), and cultured in 5% CO₂ at 37℃ in keratinocyte growth medium (GIBCO, Carlsbad, CA, USA) containing 0.2 ng/mL human recombinant epidermal growth factor and 50 µg/mL bovine pituitary extract. Cells were treated with gemigliptin (200 or 400 µg/mL) in culture medium with or without TGF-β (5 ng/mL; Sigma, St. Louis, MO, USA) for 48 hours. Cells were subsequently processed for the isolation of protein as described below.

Western blot analysis

For protein preparation, cells and kidney tissue were suspended in radioimmunoprecipitation assay buffer. The cells were then lysed on ice for 30 minutes, and the cell lysate was collected by centrifugation at 15,000×g for 10 minutes. Protein quantitation was performed using a Bio-Rad Protein Assay kit (Bio-Rad, Richmond, CA, USA). Then, 30 µg of proteins were electrophoresed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and electrotransferred to polyvinylidene fluoride membranes (Millipore, Bedford, MA, USA). After blocking with 5% skimmed milk in Tris-buffered saline containing Tween 20 (0.1%) for 1 hour, the membrane was incubated with anti-fibronectin (1:1,000; BD Biosciences), anti-PAI-1 (1:1,000; BD Biosciences), anti-type I collagen (1:1,000; Abcam), anti-α smooth muscle actin (α-SMA) (1:1,000; Sigma), anti-NLRP3 (1:1,000; Novus Biologicals), anti-ASC (1:1,000; Santa Cruz Biotechnology), anti-caspase-1 (1:1,000; Santa Cruz Biotechnology), anti-IL-1β (1:1,000; Santa Cruz Biotechnology), and anti-NF-κB (1:1,000; Cell Signaling Technology) polyclonal antibodies at 4℃ with gentle shaking overnight. Expression was detected by horseradish peroxidase-linked secondary antibody (Santa Cruz Biotechnology) using the enhanced chemiluminescence Western Blotting Detection system, according to the manufacturer's instructions (Amersham, Buckinghamshire, UK). The membrane was reblotted with anti-β-tubulin antibody to verify equal loading of the protein in each lane. Densitometric measurements of the bands were made using the UN-SCAN-IT digitizing program (Silk Scientific Corp., Orem, UT, USA).

Statistical analysis

Data were evaluated using analysis of variance followed by a post hoc least significant difference test and expressed as mean±standard error of mean. Values of P<0.05 were considered statistically significant. All experiments were performed at least three times.

Ethical statements

All procedures were performed in accordance with institutional guidelines for animal research [18]. This article does not contain examinations performed on human participants. Then, ethical approval was not necessary.

RESULTS

Gemigliptin ameliorates UUO-induced renal fibrosis

First, we examined the effect of gemigliptin on UUO-induced renal fibrosis. H&E and Sirius red staining showed that UUO-induced tubular atrophy and tubulointerstitial fibrosis were significantly attenuated by treatment with gemigliptin (Fig. 1A). IHC staining demonstrated that gemigliptin reduced UUO-induced expression of fibronectin, PAI-1, and type I collagen (Fig. 1B). The effect of gemigliptin on UUO-induced expression of fibrogenic proteins was additionally confirmed by Western blot analysis (Fig. 1C and D).

Gemigliptin attenuates the UUO-induced NLRP3 inflammasome

To investigate the effect of gemigliptin on NLRP3 inflammasome activation in renal fibrosis, we analyzed the levels of NLRP3 inflammasome components NLRP3, ASC, caspase-1, and mature IL-1β in UUO kidneys. IHC staining revealed that the levels of NLRP3, ASC, caspase-1, and IL-1β were increased after ureteral obstruction. By contrast, activation of the NLRP3 inflammasome in UUO kidneys was inhibited by gemigliptin treatment (Fig. 2A). Consistent with the IHC staining results, as determined by Western blot, the protein levels of NLRP3, ASC, caspase-1, and mature IL-1β were lower in gemigliptin-treated UUO kidneys than in vehicle-treated kidneys (Fig. 2B and C).

Gemigliptin inhibits expression of TGF-β-stimulated profibrotic- and NLRP3 inflammasome-related proteins

Given that TGF-β is a primary pathogenic factor in renal fibrosis [19], we evaluated whether gemigliptin had an effect on the level of TGF-β-induced profibrotic proteins in cultured renal cells. As expected, TGF-β treatment increased protein levels of type I collagen, α-SMA, and PAI-1 in HK-2 cells. Gemigliptin-treated HK-2 cells showed markedly inhibited TGF-β-stimulated profibrotic protein level in a dose-dependent manner (Fig. 3A and B). Moreover, gemigliptin inhibited TGF-β-induced upregulation of NLRP3, ASC, caspase-1, and IL-1β in a dose-dependent manner (Fig. 3C and D). These results suggest that gemigliptin has a renoprotective effect by suppressing the activation of the NLRP3 inflammasome.

Gemigliptin inhibits NF-κB activation in vivo and in vitro

To evaluate the mechanism by which gemigliptin attenuates UUO-induced extracellular matrix (ECM) accumulation and NLRP3 inflammasome activation, we examined whether NF-κB activation (phosphorylated NF-κB) was induced in vivo by UUO, or in vitro by TGF-β treatment of HK-2 cells, and whether gemigliptin inhibited its activation. Furthermore, to assess the contributions of local DPP-4 on UUO-induced renal fibrosis, we also examined renal DPP-4 levels. IHC staining showed areas of staining of phosphorylated NF-κB and DPP-4 were increased in sections of UUO kidney, but these activation was significantly reduced by gemigliptin treatment (Fig. 4A). This inhibitory effect of gemigliptin on NF-κB activation was further confirmed by Western blot analysis (Fig. 4B and C). In accordance with the in vivo findings, gemigliptin effectively inhibited TGF-β-stimulated NF-κB phosphorylation in HK-2 cells in a dose-dependent manner (Fig. 4D and E).

DISCUSSION

In the present study, we demonstrated that gemigliptin had an apparent preventive effect on renal fibrosis. This study showed that gemigliptin abrogated UUO-induced ECM accumulation. Furthermore, gemigliptin inhibited NLRP3 inflammasome activation and subsequent proinflammatory cytokine production in the UUO kidney. Collectively, the renoprotective effect of gemigliptin appears to the consequence of down-regulated fibrotic gene expression via the suppression of TGF-β/NF-κB-induced NLRP3 inflammasome activation.

There is increasing evidence that examination of NLRP3 inflammasome activation offers new insights into the variable pathogenesis of renal fibrosis [20]. In a mouse model of crystal nephropathy, intratubular crystal formation triggers intrarenal inflammasome activation, which can be abrogated by a NLRP3-specific inflammasome inhibitor [21], while in a mouse model of type 1 and 2 diabetes mellitus, increased levels of NLRP3, ASC1, and caspase-1 demonstrate NLRP3 inflammasome activation in the diabetic kidney, which can be inhibited by saxagliptin halting progression of nephropathy [22]. Furthermore, it is known that IL-1β, which is produced by the activation of the NLRP3 inflammasome, plays an important role in development and progression of renal fibrosis [23]. Consistent with previous results, the present study also revealed that NLRP3 inflammasome activation and inflammasome-dependent IL-1β production is increased in UUO-induced fibrotic kidneys, and suppressed in the kidneys of gemigliptin-treated mice. In accordance with the in vivo finding, gemigliptin inhibited TGF-β-stimulated ECM proteins as well as inflammasome-related proteins in cultured renal tubular cells.

The proinflammatory transcription factor NF-κB regulates multiple aspects of innate and adaptive immune responses [24]. In the context of the inflammasome, NF-κB is critical for the priming signal of NLRP3 inflammasome activation and functions by inducing the transcriptional regulation of NLRP3 and pro-IL-1β in response to inflammatory signals [25]. Considering that TGF-β is a major player in renal fibrosis and it activates NF-κB signaling, targeting NF-κB could lead to amelioration of TGF-β-induced renal fibrosis [26,27]. Previous reports identified that the anti-inflammatory function of DPP-4 inhibitors is at least in part mediated by NF-κB inhibition [28]. In the present study, we found that phosphorylation of NF-κB was increased in the UUO-induced fibrotic kidney and in TGF-β-stimulated renal cells. Treatment with gemigliptin abrogated NF-κB activation, which provided evidence that the renoprotective effect of gemigliptin on renal fibrosis via the NLRP3 inflammasome was mediated by down-regulation of NF-κB signaling.

Our results agree with those of previous studies, which demonstrated that DPP-4 inhibition attenuates upregulation of DPP-4 immunolabeling in the fibrotic kidney compared with control kidney [7,29]. Previous reports demonstrated that exogenous TGF-β treatment enhanced DPP-4 activity in proximal tubule cells [29] and local DPP-expression increases inflammation by binding to caveolinn-1 and activating NF-κB [30]. Therefore, our data support the possibility that enhanced DPP-4 levels contribute to NF-κB activation and subsequently priming NLRP3 inflammasome in UUO-induced fibrotic kidney. However, we cannot exclude other possible mechanisms responsible for the renoprotective effect of gemigliptin such as regulation of GLP-1R expression or substrate including GLP-1, stromal cell-derived factor 1α (SDF-1α) [31,32,33]. Considering that administration of gemigliptin increased serum GLP-1 level in UUO mice (data not shown), GLP-1 may mediate some of the beneficial effect of gemigliptin. Further investigation would be required for confirming direct contribution of DPP-4 on inflammasome and renal fibrosis.

In summary, we demonstrated that gemigliptin has a renoprotective effect on renal fibrosis by regulation of the NLRP3 inflammasome. Inhibition of the NLRP3 inflammasome is the target for the prevention of renal fibrosis progression. Therefore, the present study provides the rationale for further study to elucidate the effect of gemigliptin in inhibition of the NLRP3 inflammasome in the clinical setting for preventing CKD as well as DKD.

ACKNOWLEDGMENTS

This work was supported by the National Research Foundation of Korea (NRF) grants (NRF-2017M3A9G7073086 and NRF-2018R1A2A1A05077703 and NRF-2018R1C1B6008955) funded by the Korea government (Ministry of Science and ICT), NRF grant (NRF-2017R1A6A3A04010231) funded by the Ministry of Education, and grants (HI16C1501 and HI15C0001) from the Korea Health technology R&D Project through the Korea Health Industry Development Institute, funded by the Ministry of Health and Welfare, Republic of Korea.

NOTES

CONFLICTS OF INTEREST: No potential conflict of interest relevant to this article was reported.

AUTHOR CONTRIBUTIONS:

Conception or design: I.K.L., G.S.J., K.G.P.
Acquisition, analysis, or interpretation of data: J.B.S., Y.K.C., H.I.W., Y.A.J., S.L., S.L., M.P., I.K.L.
Drafting the work or revising: J.B.S., Y.K.C., G.S.J., K.G.P.
Final approval of the manuscript: G.S.J., K.G.P.

REFERENCES

1. Kim KS, Park SW, Cho YW, Kim SK. Higher prevalence and progression rate of chronic kidney disease in elderly patients with type 2 diabetes mellitus. Diabetes Metab J 2018;42:224-232.

2. Nangaku M. Mechanisms of tubulointerstitial injury in the kidney: final common pathways to end-stage renal failure. Intern Med 2004;43:9-17.

3. Vilaysane A, Chun J, Seamone ME, Wang W, Chin R, Hirota S, Li Y, Clark SA, Tschopp J, Trpkov K, Hemmelgarn BR, Beck PL, Muruve DA. The NLRP3 inflammasome promotes renal inflammation and contributes to CKD. J Am Soc Nephrol 2010;21:1732-1744.

4. Gong W, Mao S, Yu J, Song J, Jia Z, Huang S, Zhang A. NLRP3 deletion protects against renal fibrosis and attenuates mitochondrial abnormality in mouse with 5/6 nephrectomy. Am J Physiol Renal Physiol 2016;310:F1081-F1088.

5. Tsuprykov O, Ando R, Reichetzeder C, von Websky K, Antonenko V, Sharkovska Y, Chaykovska L, Rahnenführer J, Hasan AA, Tammen H, Alter M, Klein T, Ueda S, Yamagishi SI, Okuda S, Hocher B. The dipeptidyl peptidase inhibitor linagliptin and the angiotensin II receptor blocker telmisartan show renal benefit by different pathways in rats with 5/6 nephrectomy. Kidney Int 2016;89:1049-1061.

6. Shi S, Koya D, Kanasaki K. Dipeptidyl peptidase-4 and kidney fibrosis in diabetes. Fibrogenesis Tissue Repair 2016;9:1.

7. Kanasaki K, Shi S, Kanasaki M, He J, Nagai T, Nakamura Y, Ishigaki Y, Kitada M, Srivastava SP, Koya D. Linagliptin-mediated DPP-4 inhibition ameliorates kidney fibrosis in streptozotocin-induced diabetic mice by inhibiting endothelial-to-mesenchymal transition in a therapeutic regimen. Diabetes 2014;63:2120-2131.

8. Uchida T, Oda T, Matsubara H, Watanabe A, Takechi H, Oshima N, Sakurai Y, Kumagai H. Renoprotective effects of a dipeptidyl peptidase 4 inhibitor in a mouse model of progressive renal fibrosis. Ren Fail 2017;39:340-349.

9. Jung GS, Jeon JH, Choe MS, Kim SW, Lee IK, Kim MK, Park KG. Renoprotective effect of gemigliptin, a dipeptidyl peptidase-4 inhibitor, in streptozotocin-induced type 1 diabetic mice. Diabetes Metab J 2016;40:211-221.

10. He Y, Hara H, Nunez G. Mechanism and regulation of NLRP3 inflammasome activation. Trends Biochem Sci 2016;41:1012-1021.

11. Anders HJ, Muruve DA. The inflammasomes in kidney disease. J Am Soc Nephrol 2011;22:1007-1018.

12. Chang A, Ko K, Clark MR. The emerging role of the inflammasome in kidney diseases. Curr Opin Nephrol Hypertens 2014;23:204-210.

13. Wang W, Wang X, Chun J, Vilaysane A, Clark S, French G, Bracey NA, Trpkov K, Bonni S, Duff HJ, Beck PL, Muruve DA. Inflammasome-independent NLRP3 augments TGF-β signaling in kidney epithelium. J Immunol 2013;190:1239-1249.

14. Lorenz G, Darisipudi MN, Anders HJ. Canonical and non-canonical effects of the NLRP3 inflammasome in kidney inflammation and fibrosis. Nephrol Dial Transplant 2014;29:41-48.

15. Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 2002;10:417-426.

16. Choi SH, Leem J, Park S, Lee CK, Park KG, Lee IK. Gemigliptin ameliorates Western-diet-induced metabolic syndrome in mice. Can J Physiol Pharmacol 2017;95:129-139.

17. Choi SH, Park S, Oh CJ, Leem J, Park KG, Lee IK. Dipeptidyl peptidase-4 inhibition by gemigliptin prevents abnormal vascular remodeling via NF-E2-related factor 2 activation. Vascul Pharmacol 2015;73:11-19.

18. Jung GS, Kim MK, Jung YA, Kim HS, Park IS, Min BH, Lee KU, Kim JG, Park KG, Lee IK. Clusterin attenuates the development of renal fibrosis. J Am Soc Nephrol 2012;23:73-85.

19. Zeisberg M, Neilson EG. Mechanisms of tubulointerstitial fibrosis. J Am Soc Nephrol 2010;21:1819-1834.

20. Anders HJ, Lech M. NOD-like and Toll-like receptors or inflammasomes contribute to kidney disease in a canonical and a non-canonical manner. Kidney Int 2013;84:225-228.

21. Ludwig-Portugall I, Bartok E, Dhana E, Evers BD, Primiano MJ, Hall JP, Franklin BS, Knolle PA, Hornung V, Hartmann G, Boor P, Latz E, Kurts C. An NLRP3-specific inflammasome inhibitor attenuates crystal-induced kidney fibrosis in mice. Kidney Int 2016;90:525-539.

22. Birnbaum Y, Bajaj M, Qian J, Ye Y. Dipeptidyl peptidase-4 inhibition by saxagliptin prevents inflammation and renal injury by targeting the Nlrp3/ASC inflammasome. BMJ Open Diabetes Res Care 2016;4:e000227.

23. Kolb M, Margetts PJ, Anthony DC, Pitossi F, Gauldie J. Transient expression of IL-1beta induces acute lung injury and chronic repair leading to pulmonary fibrosis. J Clin Invest 2001;107:1529-1536.

24. Oeckinghaus A, Ghosh S. The NF-kappaB family of transcription factors and its regulation. Cold Spring Harb Perspect Biol 2009;1:a000034.

25. Liu T, Zhang L, Joo D, Sun SC. NF-κB signaling in inflammation. Signal Transduct Target Ther 2017;2.

26. Sato S, Sanjo H, Takeda K, Ninomiya-Tsuji J, Yamamoto M, Kawai T, Matsumoto K, Takeuchi O, Akira S. Essential function for the kinase TAK1 in innate and adaptive immune responses. Nat Immunol 2005;6:1087-1095.

27. Kim JY, Omori E, Matsumoto K, Nunez G, Ninomiya-Tsuji J. TAK1 is a central mediator of NOD2 signaling in epidermal cells. J Biol Chem 2008;283:137-144.

28. Avogaro A, Fadini GP. The effects of dipeptidyl peptidase-4 inhibition on microvascular diabetes complications. Diabetes Care 2014;37:2884-2894.

29. Min HS, Kim JE, Lee MH, Song HK, Kang YS, Lee MJ, Lee JE, Kim HW, Cha JJ, Chung YY, Hyun YY, Han JY, Cha DR. Dipeptidyl peptidase IV inhibitor protects against renal interstitial fibrosis in a mouse model of ureteral obstruction. Lab Invest 2014;94:598-607.

30. Zhong J, Maiseyeu A, Davis SN, Rajagopalan S. DPP4 in cardiometabolic disease: recent insights from the laboratory and clinical trials of DPP4 inhibition. Circ Res 2015;116:1491-1504.

31. Fujita H, Taniai H, Murayama H, Ohshiro H, Hayashi H, Sato S, Kikuchi N, Komatsu T, Komatsu K, Komatsu K, Narita T, Yamada Y. DPP-4 inhibition with alogliptin on top of angiotensin II type 1 receptor blockade ameliorates albuminuria via up-regulation of SDF-1α in type 2 diabetic patients with incipient nephropathy. Endocr J 2014;61:159-166.

32. Stokman G, Stroo I, Claessen N, Teske GJ, Florquin S, Leemans JC. SDF-1 provides morphological and functional protection against renal ischaemia/reperfusion injury. Nephrol Dial Transplant 2010;25:3852-3859.

33. Joo KW, Kim S, Ahn SY, Chin HJ, Chae DW, Lee J, Han JS, Na KY. Dipeptidyl peptidase IV inhibitor attenuates kidney injury in rat remnant kidney. BMC Nephrol 2013;14:98.

Fig. 1

Effect of gemigliptin (Gemi) on unilateral ureteral obstruction (UUO)-induced renopathological changes. (A) Representative images of H&E and Sirius red staining of kidney tissue sections from control (CON) mice and UUO mice without or with Gemi treatment (300 mg/kg; UUO+Gemi). The number of atrophic tubules was determined by measuring abnormal and dilated tubular basement membranes in five random fields of H&E-stained sections under high power magnification (×200). Areas of positive staining with Sirius red were quantitated by computer-based morphometric analysis. All morphometric data were normalized against the corresponding values in CON animals. Data in all bar graphs are expressed as fold increase relative to the CON (n=6 in each group). (B) Representative images of immunohistochemical staining for fibronectin, plasminogen activator inhibitor 1 (PAI-1), and type I collagen in kidney tissue sections from CON mice or UUO mice without or with Gemi treatment (300 mg/kg; UUO+Gemi). Areas of positive staining with fibronectin, PAI-1, and type I collagen antibodies were quantitated by computer-based morphometric analysis. All data were expressed as the mean±standard error of the mean (SEM) of five random fields from each kidney section (n=6 in each group). (C, D) Representative Western blot analysis of renal protein levels of fibronectin, PAI-1, and type I collagen normalized to β-tubulin. The data are represented as the mean±SEM of three independent measurements (n=6 in each group). ^aP<0.001, ^bP<0.01 compared with CON mice, ^cP<0.001, ^dP<0.01 compared with UUO-induced mice.

Fig. 2

Effect of gemigliptin (Gemi) on the unilateral ureteral obstruction (UUO)-induced inflammasome. (A) Representative images of immunohistochemical staining for NOD-like receptor protein 3 (NLRP3), apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC), caspase-1, and interleukin 1β (IL-1β) in kidney tissue sections from control (CON) mice or UUO mice without or with Gemi treatment (300 mg/kg; UUO+Gemi). Areas of positive staining for NLRP3, ASC, caspase-1, and IL-1β were quantitated by computer-based morphometric analysis. All data were expressed as the mean±standard error of the mean (SEM) of five random fields from each kidney section (n=6 in each group). (B, C) Representative Western blot analysis of renal protein levels of NLRP3, ASC, caspase-1, and IL-1β normalized to β-tubulin. The data are represented as the mean±SEM of three independent measurements (n=6 in each group). ^aP<0.001, ^bP<0.01, ^cP<0.05 compared with CON mice, ^dP<0.001, ^eP<0.01, ^fP<0.05 compared with UUO-induced mice.

Fig. 3

Effects of gemigliptin (Gemi) on transforming growth factor-β (TGF-β)-stimulated fibrosis- and inflammasome-related gene expression in human proximal tubule epithelial cells. (A, B) Representative Western blot analyses of the level of type I collagen, α smooth muscle actin (α-SMA), and plasminogen activator inhibitor 1 (PAI-1) in TGF-β-stimulated human renal proximal tubule cells (HK-2) normalized to β-tubulin. Quantitation of Western blot analyses in TGF-β-stimulated HK-2 cells. Data are the mean±standard error of the mean (SEM) of three independent measurements (three separate experiments). (C, D) Representative Western blot analyses of the level of NOD-like receptor protein 3 (NLRP3), apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC), caspase-1, and interleukin 1β (IL-1β) in TGF-β-stimulated HK-2 cells. Quantitation of Western blot analyses of TGF-β-stimulated HK-2 cells. ^aP<0.001, ^bP<0.01, ^cP<0.05 compared with control, ^dP<0.001, ^eP<0.01, ^fP<0.05 compared with TGF-β alone.

Fig. 4

Effects of gemigliptin (Gemi) on nuclear factor-κB (NF-κB) activation in vivo and in vitro. (A) Representative images of immunohistochemical staining for phosphorylated NF-κB (p-NF-κB) and CD-26 in kidney tissue sections from control (CON) mice or unilateral ureteral obstruction (UUO) mice without or with Gemi treatment (300 mg/kg; UUO+Gemi). Areas of positive staining with p-NF-κB antibody were quantitated by computer-based morphometric analysis. All data were expressed as the mean±standard error of the mean (SEM) of five random fields from each kidney section (n=6 in each group). (B, C) Representative Western blot analysis of levels of p-NF-κB normalized to β-tubulin. The data are represented as the mean±SEM of three independent measurements (n=6 in each group). (D, E) Representative Western blot analyses of the level of p-NF-κB in transforming growth factor-β (TGF-β)-stimulated human renal proximal tubule cells (HK-2) normalized to β-tubulin. Quantitation of Western blot analyses in TGF-β-stimulated HK-2 cells. Data are the mean±SEM of three independent measurements (three separate experiments). ^aP<0.001 compared with CON mice, ^bP<0.001 compared with UUO-induced mice, ^cP<0.001 compared with control, ^dP<0.01 compared with TGF-β alone.